ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: PUB200

Fibroblast Growth Factor 23 (FGF-23) Regulates HK-2 Cell Proliferation, Migration, and Response to TGF-β1

Session Information

Category: Chronic Kidney Disease (Non-Dialysis)

  • 308 CKD: Mechanisms of Tubulointerstitial Fibrosis

Authors

  • Lawson, Jack S., Royal Veterinary College, London, United Kingdom
  • Syme, Harriet M., Royal Veterinary College, London, United Kingdom
  • Wheeler-Jones, Caroline Pd, Royal Veterinary College, London, United Kingdom
  • Elliott, Jonathan, Royal Veterinary College, London, United Kingdom
Background

Plasma FGF-23 concentration increases early in the course of chronic kidney disease (CKD), and rises progressively with deteriorating renal function. Elevated FGF-23 is associated with progression of CKD, and may play a direct role in the development of renal injury and tubulointerstitial fibrosis. The aims of this study were to investigate the effects of FGF-23 on proliferation, migration, viability and pro-fibrotic gene expression in a human tubular epithelial cell line (HK-2), and to determine whether FGF-23 modulates the transcriptional and functional effects of TGF-β1.

Methods

HK-2 cells were incubated with FGF-23 (0.1-100 ng/ml) ± 10 ng/ml TGF-β1 for 72 h. ERK1/2 phosphorylation was measured by immunoblotting. Expression of E-cadherin, N-cadherin, connective tissue growth factor (CTGF), collagen 1α1 (col1α1) and TGF-β1 was assessed by RT-qPCR (normalised to GAPDH/RPS7). Cell migration was measured using a scratch wound healing assay, and proliferation and viability monitored by cell counting, crystal violet staining and measurement of caspase 3/7 activity. The MEK inhibitor PD184352 (1 μM) and the FGF receptor 1 (FGFR1) antagonist SU5402 (10 μM) were used to investigate involvement of MEK-ERK signalling and FGFR activation, respectively.

Results

FGF-23 increased ERK phosphorylation and stimulated cell proliferation, which was completely attenuated by PD184352. Scratch wound closure was stimulated by FGF-23 in a concentration dependent manner, and this was blocked by SU5402. TGF-β1 decreased wound closure, and this was partially ameliorated by FGF-23. FGF-23 suppressed col1α1 expression, and at 100 ng/ml partially inhibited TGF-β1-driven increases in col1α1, N-cadherin, and CTGF expression. FGF-23 and TGF-β1 each inhibited E-cadherin expression, but there was no additive inhibitory effect. FGF-23 did not modify TGF-β1 mRNA expression or TGF-β1-mediated caspase 3/7 activation.

Conclusion

FGF-23 stimulates migration and proliferation of HK-2 cells most likely through engagement of FGFR1 and MEK-ERK pathway activation, and partially reverses pro-fibrotic and anti-repair responses to TGF-β1. These results suggest FGF-23 facilitates tubular repair and regeneration processes. The relevance of these findings to progressive nephron loss in the CKD patient warrants further study to establish their translational potential.

Funding

  • Commercial Support – Elanco Animal Health